Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.
Peterlin P, Le Bris Y, Turlure P, Chevallier P, Ménard A, Gourin MP, Dumas PY, Thepot S, Berceanu A, Park S, Hospital MA, Cluzeau T, Bouzy S, Torregrosa-Diaz JM, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Chevret S, Béné MC, Fenaux P. Peterlin P, et al. Among authors: cluzeau t. Lancet Haematol. 2023 Jul;10(7):e521-e529. doi: 10.1016/S2352-3026(23)00090-X. Epub 2023 May 25. Lancet Haematol. 2023. PMID: 37245522 Clinical Trial.
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Swoboda DM, et al. Among authors: cluzeau t. Leukemia. 2022 Apr;36(4):1189-1192. doi: 10.1038/s41375-021-01486-w. Epub 2022 Jan 3. Leukemia. 2022. PMID: 34975158 No abstract available.
[We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment].
Barrière J, Audigier-Valette C, Borchiellini D, Hoch B, Castelnau O, Francois E, Gastaud L, Skaf R, Berdah JF, Marie W, Lescaut W, Peyrade F, Cluzeau T, Cassuto O, Carles M. Barrière J, et al. Among authors: cluzeau t. Bull Cancer. 2021 Apr;108(4):341-342. doi: 10.1016/j.bulcan.2021.02.003. Epub 2021 Mar 5. Bull Cancer. 2021. PMID: 33741139 Free PMC article. French. No abstract available.
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.
Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debré I, Alexe G, Benoist JF, Pruvost A, Pikman Y, Qi J, Schlageter MH, Micol JB, Roti G, Cluzeau T, Dombret H, Preudhomme C, Fenouille N, Benajiba L, Golan HM, Stegmaier K, Lobry C, Wood KC, Itzykson R, Puissant A. Su A, et al. Among authors: cluzeau t. Cancer Discov. 2020 Dec;10(12):1894-1911. doi: 10.1158/2159-8290.CD-19-0970. Epub 2020 Aug 21. Cancer Discov. 2020. PMID: 32826232 Free PMC article.
Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.
Dubois A, Ginet C, Furstoss N, Belaid A, Hamouda MA, El Manaa W, Cluzeau T, Marchetti S, Ricci JE, Jacquel A, Luciano F, Driowya M, Benhida R, Auberger P, Robert G. Dubois A, et al. Among authors: cluzeau t. Oncotarget. 2016 May 3;7(18):26120-36. doi: 10.18632/oncotarget.8319. Oncotarget. 2016. PMID: 27027430 Free PMC article.
Mechanism of action of the multikinase inhibitor Foretinib.
Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P. Dufies M, et al. Among authors: cluzeau t. Cell Cycle. 2011 Dec 1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1. Cell Cycle. 2011. PMID: 22101270
132 results